- Home
- AVTX vs ACRS Comparison
AVTX vs ACRS Comparison
Compare AVTX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | ACRS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 311.0M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AVTX | ACRS |
|---|---|---|
| Price | $14.95 | $3.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $36.80 | $9.75 |
| AVG Volume (30 Days) | 745.9K | ★ 2.6M |
| Earning Date | 03-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $3.39 | $1.05 |
| 52 Week High | $20.72 | $4.89 |
Technical Indicators
Market Signals| Indicator | AVTX | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 56.27 |
| Support Level | $13.38 | $3.16 |
| Resistance Level | $16.40 | $3.86 |
| Average True Range (ATR) | 1.08 | 0.25 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 48.03 | 66.89 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.